Bayer AG NA (XETRA:BAYN) — Market Cap & Net Worth
Market Cap & Net Worth: Bayer AG NA (BAYN)
Bayer AG NA (XETRA:BAYN) has a market capitalization of $47.21 Billion (€40.38 Billion) as of April 19, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #528 globally and #71 in its home market, demonstrating a 1.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bayer AG NA's stock price €41.10 by its total outstanding shares 982424082 (982.42 Million).
Bayer AG NA Market Cap History: 2015 to 2026
Bayer AG NA's market capitalization history from 2015 to 2026. Data shows change from $98.27 Billion to $47.21 Billion (-6.35% CAGR).
Index Memberships
Bayer AG NA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
HDAX Performance
GDAXHI
|
$1.01 Trillion | 4.45% | #6 of 99 |
|
HDAX Price
GDAXHIP
|
$1.04 Trillion | 4.34% | #6 of 102 |
|
DAX Index
GDAXI
|
$850.89 Billion | 5.31% | #6 of 40 |
|
DAX Price
GDAXIP
|
$850.89 Billion | 5.31% | #6 of 40 |
|
STOXX Europe Large 200 EUR Price
LCXP
|
$5.55 Trillion | 0.81% | #36 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$5.55 Trillion | 0.81% | #36 of 182 |
Weight: Bayer AG NA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bayer AG NA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bayer AG NA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.48x
Bayer AG NA's market cap is 0.48 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $98.27 Billion | $46.32 Billion | $4.11 Billion | 2.12x | 23.91x |
| 2016 | $86.26 Billion | $46.77 Billion | $4.53 Billion | 1.84x | 19.04x |
| 2017 | $92.80 Billion | $35.02 Billion | $7.34 Billion | 2.65x | 12.65x |
| 2018 | $56.45 Billion | $39.59 Billion | $1.70 Billion | 1.43x | 33.30x |
| 2019 | $71.11 Billion | $43.55 Billion | $2.43 Billion | 1.63x | 29.26x |
| 2020 | $49.21 Billion | $41.40 Billion | -$15.56 Billion | 1.19x | N/A |
| 2021 | $49.87 Billion | $44.08 Billion | $1.00 Billion | 1.13x | 49.87x |
| 2022 | $52.96 Billion | $50.74 Billion | $4.15 Billion | 1.04x | 12.76x |
| 2023 | $38.47 Billion | $47.64 Billion | -$2.94 Billion | 0.81x | N/A |
| 2024 | $22.18 Billion | $46.61 Billion | -$2.55 Billion | 0.48x | N/A |
Competitor Companies of BAYN by Market Capitalization
Companies near Bayer AG NA in the global market cap rankings as of April 19, 2026.
Key companies related to Bayer AG NA by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $829.71 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #19 globally with a market cap of $564.21 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #33 globally with a market cap of $368.45 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #45 globally with a market cap of $317.50 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $829.71 Billion | $927.03 |
| #19 | Johnson & Johnson | NYSE:JNJ | $564.21 Billion | $234.18 |
| #33 | AbbVie Inc | NYSE:ABBV | $368.45 Billion | $208.38 |
| #45 | AstraZeneca PLC | NASDAQ:AZN | $317.50 Billion | $204.80 |
Bayer AG NA Historical Marketcap From 2015 to 2026
Between 2015 and today, Bayer AG NA's market cap moved from $98.27 Billion to $ 47.21 Billion, with a yearly change of -6.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €47.21 Billion | +11.05% |
| 2025 | €42.51 Billion | +91.62% |
| 2024 | €22.18 Billion | -42.34% |
| 2023 | €38.47 Billion | -27.36% |
| 2022 | €52.96 Billion | +6.20% |
| 2021 | €49.87 Billion | +1.34% |
| 2020 | €49.21 Billion | -30.79% |
| 2019 | €71.11 Billion | +25.96% |
| 2018 | €56.45 Billion | -39.17% |
| 2017 | €92.80 Billion | +7.58% |
| 2016 | €86.26 Billion | -12.22% |
| 2015 | €98.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of Bayer AG NA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.21 Billion USD |
| MoneyControl | $47.21 Billion USD |
| MarketWatch | $47.21 Billion USD |
| marketcap.company | $47.21 Billion USD |
| Reuters | $47.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast age… Read more